Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
This is a short extract from a report by CNBC. The full text stays with the publisher — follow the link to read it there.
Read at source